Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Altimmune, Inc is a biotechnology business based in the US. Altimmune shares (ALT) are listed on the NASDAQ and all prices are listed in US Dollars. Altimmune employs 25 staff and has a trailing 12-month revenue of around USD$4.2 million.
Since the stock market crash in March caused by coronavirus, Altimmune's share price has had significant positive movement.
Its last market close was USD$14.35, which is 87.74% up on its pre-crash value of USD$1.76 and 796.88% up on the lowest point reached during the March crash when the shares fell as low as USD$1.6.
If you had bought USD$1,000 worth of Altimmune shares at the start of February 2020, those shares would have been worth USD$1,676.13 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$8,153.38.
|Latest market close||USD$14.35|
|52-week range||USD$1.51 - USD$35.1|
|50-day moving average||USD$19.7228|
|200-day moving average||USD$11.39|
|Wall St. target price||USD$55|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.161|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-12)||N/A|
|1 month (2020-08-21)||-40.31%|
|3 months (2020-06-19)||93.92%|
|6 months (2020-03-23)||386.44%|
|1 year (2019-09-20)||580.09%|
|2 years (2018-09-21)||-45.21%|
|3 years (2017-09-21)||456.18%|
|5 years (2015-09-21)||876.19%|
Valuing Altimmune stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Altimmune's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Altimmune's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Altimmune shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$4.2 million|
|Gross profit TTM||USD$-11,284,062|
|Return on assets TTM||-20.2%|
|Return on equity TTM||-52.58%|
|Market capitalisation||USD$464.7 million|
TTM: trailing 12 months
There are currently 1.9 million Altimmune shares held short by investors – that's known as Altimmune's "short interest". This figure is 26.9% down from 2.6 million last month.
There are a few different ways that this level of interest in shorting Altimmune shares can be evaluated.
Altimmune's "short interest ratio" (SIR) is the quantity of Altimmune shares currently shorted divided by the average quantity of Altimmune shares traded daily (recently around 3.0 million). Altimmune's SIR currently stands at 0.64. In other words for every 100,000 Altimmune shares traded daily on the market, roughly 640 shares are currently held short.
However Altimmune's short interest can also be evaluated against the total number of Altimmune shares, or, against the total number of tradable Altimmune shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Altimmune's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Altimmune shares in existence, roughly 30 shares are currently held short) or 0.0365% of the tradable shares (for every 100,000 tradable Altimmune shares, roughly 37 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Altimmune.
Find out more about how you can short Altimmune stock.
We're not expecting Altimmune to pay a dividend over the next 12 months.
Altimmune's shares were split on a 1:30 basis on 14 September 2018. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Altimmune shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Altimmune shares which in turn could have impacted Altimmune's share price.
Over the last 12 months, Altimmune's shares have ranged in value from as little as $1.51 up to $35.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Altimmune's is 1.4228. This would suggest that Altimmune's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.